Cardiovascular Toxicities from Systemic Breast Cancer Therapy
نویسندگان
چکیده
Cardiovascular toxicity is unfortunately a potential short- or long-term sequela of breast cancer therapy. Both conventional chemotherapeutic agents such as anthracyclines and newer targeted agents such as trastuzumab can cause varying degrees of cardiac dysfunction. Type I cardiac toxicity is dose-dependent and irreversible, whereas Type II is not dose-dependent and is generally reversible with cessation of the drug. In this review, we discuss what is currently known about the cardiovascular effects of systemic breast cancer treatments, with a focus on the putative mechanisms of toxicity, the role of biomarkers, and potential methods of preventing and minimizing cardiovascular complications.
منابع مشابه
The Heartaches of Cancer Therapy: Acute and Late Cardiotoxicity in Cancer Survivors.
Survival of cancer patients has improved dramatically in the past several decades; the 5-year overall survival rate in the United States was 49% in the 1970s but rose to 67% by 2012.[1,2] Advances in cancer survival have exposed risks of death from other causes, such as cardiovascular disease (CVD), the leading cause of death in the United States and the leading cause of death in survivors of e...
متن کاملBreast cancer treatment-associated cardiovascular toxicity and effects of exercise countermeasures
Advances in breast cancer treatment have improved disease-free survival and overall survival in women with early-stage breast cancer. However, these improvements may be attenuated by the adverse cardiovascular effects associated with breast cancer adjuvant therapy. Exercise may be a potential strategy to counteract these toxicities. The purpose of this paper is to provide an overview on the adv...
متن کاملSystemic treatment in breast cancer: a primer for radiologists
UNLABELLED Cytotoxic chemotherapy, hormonal therapy and molecular targeted therapy are the three major classes of drugs used to treat breast cancer. Imaging modalities such as computed tomography (CT), magnetic resonance imaging (MRI), (18)F-FDG positron emission tomography (PET)/CT and bone scintigraphy each have a distinct role in monitoring response and detecting drug toxicities associated w...
متن کاملCardiovascular Toxicities of Breast Cancer Treatment: Emerging Issues in Cardio-Oncology
In 2015, the American Cancer Society estimates that 234,000 new cases of breast cancer will be diagnosed along with an additional 60,000 cases of carcinoma in situ. Nearly 40,000 women will die due to breast cancer annually (1). Current management options for Stage 0, I, & II breast cancer include mastectomy, breast conserving surgery (BCS), or breast conserving surgery followed by whole breast...
متن کاملClinical Utility of Aromatase Inhibitors as Adjuvant Treatment in Postmenopausal Early Breast Cancer
Breast cancer is the most frequently diagnosed malignancy in women, with over 200,000 new cases diagnosed each year. Adjuvant systemic endocrine therapy has demonstrated its benefits in reducing the risk of occult micro metastatic infiltration by preventing breast cancer cells from receiving endogenous estrogen stimulation. Initial adjuvant treatment with an aromatase inhibitor (AI) is consider...
متن کامل